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Renal Medullary Carcinoma 
Temidayo Adebiyi 
Overview 
In 1974, Berman described six sickle cell nephropathies: gross hematuria, papillary necrosis, 
nephrotic syndrome, renal infarction, isosthenuria, and pyelonephritis.1 In 1995, Davis et al 
described what has been suggested to be the seventh sickle cell nephropathy, renal medullary 
carcinoma (RMC)2. RMC is a malignant tumor originating from the collecting duct.3  
 
Epidemiology 
RMC is found almost exclusively in patients of African descent with sickle cell 
hemoglobinopathies, although it has been rarely reported in Caucasians (<10 cases)4-9.  It is a 
rare disease with an estimated 150 reported cases to date, mostly in patients with sickle cell 
trait or more rarely sickle cell disease.10 It appears to be more common in males with a 2:1 ratio 
observed in adults.10  In the pediatric population, the difference is more pronounced with a 5:1 
male to female ratio reported.5  
 
Pathophysiology 
The pathophysiology of RMC is incompletely understood. Swartz et al., using 
immunohistorchemical analysis, reported that in a subset of the overall 40 cases they analyzed, 
the tumors expressed TP53 (tumor protein 53), VEGF (vascular endothelial growth factor), and 
HIF (hypoxia-inducible factors).  Therefore they proposed that hypoxia in the kidney leads to 
increased expression of HIF and VEGF in the absence of normal p53 leading to neovascular 
network formation and tumor development.11 Other studies have found that SMARCB1, another 
tumor suppressor protein, is not detectable in renal medullary carcinoma by 
immunohistochemistry, suggesting that inactivation of the SMARCB1 gene may play a role in 
the pathogenesis.12 
RMC usually presents in the right kidney (>75% of cases) as a solitary poorly circumscribed 
mass (Table 1).10  On sectioning, there is often evidence of necrosis and hemorrhage. 
Microscopic examination often shows a microvesicular pattern, reminiscent of testicular yolk sac 
tumors. Sickled erythrocytes are often found within the tumor and adjacent tissues.5,13 
 
Clinical presentation 
Patient age at presentation ranges from 5 to 69 years with a mean of 19.5 RMC commonly 
presents with flank pain and hematuria. Other symptoms include dysuria, abdominal mass and 
weight loss.3-5 By the time of presentation, 95% of patients have evidence of metastasis.5 The 
most common sites for metastasis are the regional lymph nodes, adrenal glands, lung, liver, 
inferior vena cava, and peritoneum.4  
 
Differential diagnosis 
Other causes of flank pain and hematuria in a patient with sickle cell trait include papillary 
necrosis and renal infarction. Patients with sickle cell trait often develop renal insufficiency by 
the fourth decade of life, but gross hematuria due to sickle cell nephropathy is unusual and 
should be a diagnosis of exclusion. Renal infarction and papillary necrosis can lead to scarring 
and deformity but usually do not present as a mass.4 The differential diagnosis for flank pain 
and hematuria with a mass include high grade invasive urothelial carcinoma and collecting duct 
carcinoma. Neither urothelial carcinoma nor collecting duct carcinoma have an association with 
sickle cell hemoglobinopathies. Urothelial carcinoma has a mean age of presentation > 50 and 
adjacent typical urothelial carcinoma or carcinoma in situ is usually seen. Collecting duct 
carcinoma has a mean age of presentation between 50 and 55. On pathology, it has 




RMC should be considered in a patient with sickle cell hemoglobinopathy who presents with 
flank pain and hematuria.4 Imaging is the first step to determine whether a mass is present. This 
is usually done with CT scan, intravenous pyelography, or MRI. This typically reveals a tumor 
within the renal parenchyma involving the renal sinus and pelvis. The lesion’s growth is 
infiltrative resulting in an increase in overall kidney size without changing its overall shape.5,14 
On imaging, evidence of metastasis will often be present. Tissue sample is needed to make the 
diagnosis. On pathology in addition to the features mentioned above, there is usually 
neutrophilic infiltrate, intraluminal mucin, and perinephric extension. Immunohistochemical 
profile is usually positive for vimentin and CK7 and negative for CK20, Ksp-cadherin, and 
Pax2.14  
 
Treatment and Prognosis 
RMC has a very poor prognosis with mean survival time being less than one year and median 
survival time of 15 months after diagnosis. One option would be nephrectomy. However, this is 
usually not pursued as most patients present with evidence of metastasis. In addition, even in 
cases, where there is no evidence of metastasis, and the kidney is removed with clear margins 
and negative lymph nodes, nephrectomy bed and distant metastasis have occurred. Radiation 
therapy is also not efficacious. Multiple chemotherapy agents such as cyclophosphamide, 
doxorubicin, cisplatin, topotecan, methotrexate, vinblastine, and alpha interferon have not been 
successful in treating RMC.4,10 Kondagunta et al. studied the use of bortezomib in metastatic 
renal cell carcinoma.  Bortezomib is a proteasome inhibitor approved for treating multiple 
myeloma and mantle cell lymphoma. One patient in this trial had metastatic RMC. This patient 
received 1.3 mg/m2 of the drug twice a week for two weeks, followed by one week without the 
medication, for a total of 7 months. This patient went into remission and had no evidence of 
disease for 27 months of follow up.10,15 However, more studies are needed to identify the most 
effective therapy. 
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* All cases reported in the English literature using Medline from 1995- 2003 plus 3 additional 
subjects from the author’s institution.   






1. Berman, LB. Sickle cell nephropathy. JAMA. 1974;228:1279-1279 
 
2.  Davis, CJ, Mostofi, FK, Sesterhenn, IA. Renal medullary carcinoma: the seventh sickle 
cell nephropathy. The American journal of surgical pathology. 1995;19:1-11. 
 
3. Baig MA, Lin Y, Rasheed, J, Mittman, N. Renal medullary carcinoma. Journal of the 
national medical association. 2006;98:1171-1174 
 
4.  Warren, KE, Gidvani-Diaz, V, Duval-Arnould, B. Renal medullary carcinoma in an 
adolescent with sickle cell trait. Pediatrics. 1999;103;e22 
 
5. Srigley, JR, Delahunt, B. Uncommon and recently described renal carcinomas. Modern 
pathology. 2009;22:S2-S23 
 6. Gatalica Z, Lilleberg SL, Monzon FA, et al. Renal medullary carcinomas: histopathologic 
phenotype associated with diverse genotypes. Human pathology 2011;42:1979-88. 
 
7. Hakimi AA, Koi PT, Milhoua PM, et al. Renal medullary carcinoma: the Bronx 
experience. Urology 2007;70:878-82. 
 
8. Watanabe IC, Billis A, Guimaraes MS, et al. Renal medullary carcinoma: report of seven 
cases from Brazil. Modern pathology : an official journal of the United States and Canadian 
Academy of Pathology, Inc 2007;20:914-20. 
 
9. Simpson L, He X, Pins M, et al. Renal medullary carcinoma and ABL gene amplification. 
The Journal of urology 2005;173:1883-8. 
10. Shetty, A, Matrana, MR. Renal medullary carcinoma: A case report and brief review of 
the literature. The Ochsner journal. 2014;14:270-275. 
11. Swartz, MA, Karth, J, Schneider, DT, et al. Renal medullary carcinoma: clinical, 
pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology. 
2002;60: 1083-1089 
12. Liu, Q, Galli, S, Srinivasan, R, et al. Renal medullary carcinoma: molecular 
immunohistochemistry, and morphologic correlation. American journal of surgical pathology. 
2013;37: 368-373 
 
13. Alappan, N, Marak, C, Copra, A, et al. Renal medullary cancer in a patient with sickle 
cell trait. Case reports in oncological medicine. 2013. Article ID 129813, 4 pages, 
doi:0.1155/2013/129813. (Accessed July 1, 2014). 
 
14. Gupta, R, Billis, A, Shah, R, et al. Carcinoma of the collecting ducts of Bellini and renal 
medullary carcinoma. American journal of surgical pathology. 2012;36:1265-1278 
 
15. Kondagunta, GV, Drucker, B, Schwartz, L, et al. Phase II trial of bortezomib for patients 
with advanced renal cell carcinoma. Journal of clinical oncology. 2004; 22(18):3720-3725  
